WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2022)
Top biotech stocks in 2022 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Country
Market Cap
Shares
Institutional %
Insider %
Net Insider (L12M)
Net Insider (L3M)
INCY
INCYTE CORP
United States
$14.82B222,430,63578.76%21.24%Net BuyingNet Selling
GMAB
GENMAB A
Denmark
$20.99B65,734,14153.97%0.00%
EXEL
EXELIXIS INC
United States
$5.10B321,831,78485.08%2.75%Net SellingNet Buying
MRNA
MODERNA INC
United States
$46.19B391,199,54461.53%19.42%Net SellingNet Selling
CSBR
CHAMPIONS ONCOLOGY INC
United States
$101.82M13,522,4412.10%97.90%Net Buying
HALO
HALOZYME THERAPEUTICS INC
United States
$5.45B137,779,37078.49%21.51%Net Selling
UTHR
UNITED THERAPEUTICS CORP
United States
$9.46B45,516,29987.35%12.65%Net SellingNet Selling
VIR
VIR BIOTECHNOLOGY INC
United States
$2.53B132,637,87859.65%40.35%Net SellingNet Selling
HRMY
HARMONY BIOSCIENCES HOLDINGS INC
United States
$2.58B59,161,39759.96%40.04%Net SellingNet Selling
CPRX
CATALYST PHARMACEUTICALS INC
United States
$1.31B102,819,50473.72%17.63%Net SellingNet Selling
SESN
SESEN BIO INC
United States
$77.59M199,463,64514.26%10.29%
CORT
CORCEPT THERAPEUTICS INC
United States
$2.74B107,105,07830.56%69.44%Net BuyingNet Buying
TECH
BIO-TECHNE CORP
United States
$11.20B39,212,03393.85%6.15%Net BuyingNet Buying
VRTX
VERTEX PHARMACEUTICALS INC
United States
$75.09B256,459,48290.53%1.47%Net SellingNet Selling
XOMA
XOMA CORP
United States
$210.70M11,450,82315.12%84.88%Net BuyingNet Buying
REGN
REGENERON PHARMACEUTICALS INC
United States
$75.41B109,008,32269.59%30.41%Net BuyingNet Buying
CDMO
AVID BIOSERVICES INC
United States
$1.17B62,167,45491.92%8.08%Net SellingNet Selling
SIGA
SIGA TECHNOLOGIES INC
United States
$744.85M73,024,14729.73%70.27%Net Selling
HUMA
HUMACYTE INC
United States
$346.10M103,006,80313.05%76.68%Net SellingNet Selling
BLCM
BELLICUM PHARMACEUTICALS INC
United States
$10.16M8,611,82917.54%82.46%
BNTX
BIONTECH SE
Germany
$32.47B243,019,21613.75%0.00%
AUPH
AURINIA PHARMACEUTICALS INC
Canada
$1.06B141,892,18135.17%0.37%Net Selling
APVO
APTEVO THERAPEUTICS INC
United States
$15.02M5,090,64415.63%71.19%Net Selling
ETON
ETON PHARMACEUTICALS INC
United States
$53.63M25,297,03723.39%22.13%Net SellingNet Buying
BGNE
BEIGENE LTD
Cayman Islands
$14.16B1,349,639,4393.97%35.39%Net BuyingNet Selling
LPCN
LIPOCINE INC
United States
$38.50M88,510,79113.45%10.37%Net BuyingNet Buying
EFTR
EFFECTOR THERAPEUTICS INC
United States
$23.63M41,452,79034.97%65.03%Net SellingNet Selling
SELB
SELECTA BIOSCIENCES INC
United States
$245.87M152,713,21138.00%38.03%Net BuyingNet Selling
SLGL
SOL-GEL TECHNOLOGIES LTD
Israel
$119.35M23,129,46925.03%0.00%
DVAX
DYNAVAX TECHNOLOGIES CORP
United States
$1.30B126,473,58668.46%31.54%Net SellingNet Selling
ZLAB
ZAI LAB LTD
China
$3.43B979,087,4306.11%1.95%Net SellingNet Buying
CARA
CARA THERAPEUTICS INC
United States
$489.44M53,725,92561.63%38.37%Net SellingNet Selling
GNFT
GENFIT SA
France
$194.78M49,815,4894.16%0.00%
OCUP
OCUPHIRE PHARMA INC
United States
$41.16M20,579,7790.81%99.19%Net Buying
ATNF
180 LIFE SCIENCES CORP
United States
$25.60M37,698,9356.53%32.96%Net Buying
HCM
HUTCHMED (CHINA) LTD
Hong Kong
$1.49B864,575,3405.61%0.00%
CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC
United States
$6.74M14,070,27910.72%2.36%Net BuyingNet Buying
ABCM
ABCAM PLC
United Kingdom
$3.35B228,883,63911.69%0.00%
CLNN
CLENE INC
United States
$178.44M63,501,9845.58%78.59%Net BuyingNet Buying
AGEN
AGENUS INC
United States
$583.32M283,162,90251.80%46.89%Net BuyingNet Buying
HSTO
HISTOGEN INC
United States
$3.55M2,497,4500.00%100.00%
OPNT
OPIANT PHARMACEUTICALS INC
United States
$54.07M5,164,15112.28%87.72%Net SellingNet Selling
IMGN
IMMUNOGEN INC
United States
$1.04B220,713,09088.74%3.58%Net Buying
RPTX
REPARE THERAPEUTICS INC
Canada
$504.09M41,937,79559.35%40.65%Net Buying
MRUS
MERUS NV
Netherlands
$908.39M45,878,16776.15%16.14%Net SellingNet Buying
CLGN
COLLPLANT BIOTECHNOLOGIES LTD
Israel
$72.62M11,086,48115.67%0.00%
SPRC
SCISPARC LTD
Israel
$2.38M3,091,74015.31%0.00%
FUSN
FUSION PHARMACEUTICALS INC
Canada
$128.44M43,390,53253.18%46.82%Net SellingNet Buying
LQDA
LIQUIDIA CORP
United States
$341.12M64,362,33629.03%70.97%Net BuyingNet Buying
BMRN
BIOMARIN PHARMACEUTICAL INC
United States
$15.78B185,473,86794.63%1.38%Net SellingNet Selling
LOGC
LOGICBIO THERAPEUTICS INC
United States
$9.39M32,962,73333.54%40.63%Net Selling
LPTX
LEAP THERAPEUTICS INC
United States
$88.82M99,021,37637.96%41.94%
BYSI
BEYONDSPRING INC
United States
$37.84M38,927,56322.85%0.00%
RPRX
ROYALTY PHARMA PLC
United States
$24.49B607,219,96947.28%16.28%Net SellingNet Selling
SNDX
SYNDAX PHARMACEUTICALS INC
United States
$1.40B56,565,16587.47%12.53%Net BuyingNet Buying
DBVT
DBV TECHNOLOGIES SA
France
$340.37M94,025,19237.50%15.63%
LMNL
LIMINAL BIOSCIENCES INC
Canada
$13.04M31,042,5600.94%0.00%
GANX
GAIN THERAPEUTICS INC
United States
$37.67M11,883,3689.05%1.98%Net Buying
PTGX
PROTAGONIST THERAPEUTICS INC
United States
$404.94M49,084,06878.95%21.05%Net BuyingNet Buying
XENE
XENON PHARMACEUTICALS INC
Canada
$2.23B62,263,46391.52%4.01%Net SellingNet Selling
LEXX
LEXARIA BIOSCIENCE CORP
Canada
$14.52M5,950,9989.44%9.67%Net Buying
MIRM
MIRUM PHARMACEUTICALS INC
United States
$687.46M32,751,74830.77%69.23%Net Selling
EDIT
EDITAS MEDICINE INC
United States
$835.84M68,737,25059.22%40.78%Net SellingNet Selling
QURE
UNIQURE NV
Netherlands
$837.39M46,729,07785.69%12.99%Net SellingNet Selling
STTK
SHATTUCK LABS INC
United States
$116.97M42,382,01350.54%28.83%Net Buying
NBIX
NEUROCRINE BIOSCIENCES INC
United States
$9.83B95,639,32168.92%31.08%Net SellingNet Buying
CLSD
CLEARSIDE BIOMEDICAL INC
United States
$65.01M60,190,73122.77%45.72%Net Buying
JANX
JANUX THERAPEUTICS INC
United States
$557.03M41,663,02954.73%45.27%Net Selling
EIGR
EIGER BIOPHARMACEUTICALS INC
United States
$346.02M43,966,78352.43%47.57%Net SellingNet Selling
CGEM
CULLINAN ONCOLOGY INC
United States
$567.42M45,612,20549.26%50.74%Net BuyingNet Selling
MRVI
MARAVAI LIFESCIENCES HOLDINGS INC
United States
$6.49B255,208,83846.71%53.29%Net Buying
DARE
DARE BIOSCIENCE INC
United States
$85.67M84,820,8588.74%30.16%
ABCL
ABCELLERA BIOLOGICS INC
Canada
$2.81B285,138,64341.24%46.12%Net BuyingNet Buying
NHWK
NIGHTHAWK BIOSCIENCES INC
United States
$46.45M25,661,48813.62%24.31%
ITOS
ITEOS THERAPEUTICS INC
United States
$671.31M35,575,32362.61%37.39%Net Selling
ALEC
ALECTOR INC
United States
$780.23M82,563,92153.09%46.91%Net SellingNet Selling
INMB
INMUNE BIO INC
United States
$111.80M17,945,99511.20%40.35%Net Buying
RGNX
REGENXBIO INC
United States
$1.08B43,229,97176.02%23.98%Net SellingNet Selling
SEER
SEER INC
United States
$500.27M62,611,50660.68%39.32%Net Selling
MTEM
MOLECULAR TEMPLATES INC
United States
$40.69M56,351,64717.26%82.74%Net BuyingNet Buying
CGEN
COMPUGEN LTD
Israel
$58.39M86,624,64344.21%0.00%
PPBT
PURPLE BIOTECH LTD
Israel
$35.27M178,126,7300.07%0.00%
AVEO
AVEO PHARMACEUTICALS INC
United States
$281.76M34,614,2843.78%96.22%
NOVN
NOVAN INC
United States
$39.58M21,281,61315.47%57.62%Net Buying
ASMB
ASSEMBLY BIOSCIENCES INC
United States
$80.41M48,436,88035.49%12.75%Net SellingNet Selling
EYEN
EYENOVIA INC
United States
$67.74M34,212,86211.17%37.35%Net BuyingNet Buying
VCYT
VERACYTE INC
United States
$1.19B71,575,91864.65%35.35%Net SellingNet Selling
KMPH
KEMPHARM INC
United States
$204.55M34,493,63421.06%35.24%Net Buying
VACC
VACCITECH PLC
United Kingdom
$115.74M37,216,16212.86%44.38%Net SellingNet Selling
ARCT
ARCTURUS THERAPEUTICS HOLDINGS INC
United States
$371.54M26,576,35783.36%14.51%Net SellingNet Buying
DYAI
DYADIC INTERNATIONAL INC
United States
$53.72M28,423,1007.48%92.52%Net BuyingNet Buying
MREO
MEREO BIOPHARMA GROUP PLC
United Kingdom
$128.68M584,908,23912.69%0.00%
AFMD
AFFIMED NV
Germany
$299.02M147,300,00053.90%0.00%
AVIR
ATEA PHARMACEUTICALS INC
United States
$466.25M83,258,60369.13%25.21%Net Buying
CASI
CASI PHARMACEUTICALS INC
United States
$36.46M13,606,1302.68%97.32%Net BuyingNet Buying
VCNX
VACCINEX INC
United States
$21.03M42,664,05110.88%53.32%Net Buying
ARGX
ARGENX SE
Belgium
$19.69B55,061,50259.65%0.00%
AGIO
AGIOS PHARMACEUTICALS INC
United States
$1.57B54,818,04974.80%25.20%Net Selling
AADI
AADI BIOSCIENCE INC
United States
$287.93M21,016,83327.69%72.31%Net BuyingNet Buying
SGEN
SEAGEN INC
United States
$25.03B184,435,45645.63%54.37%Net SellingNet Selling

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Oct 2022?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the top biotech stock with a Zen Score of 73, which is 44 points higher than the biotech industry average of 29. It passed 24 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -3% over the past year, overperforming other biotech stocks by 40 percentage points.

Incyte has an average 1 year price target of $84.13, an upside of 26.29% from Incyte's current stock price of $66.61.

Incyte stock has a consensus Hold recommendation according to Wall Street analysts. Of the 9 analysts covering Incyte, 0% have issued a Strong Buy rating, 33.33% have issued a Buy, 55.56% have issued a hold, while 11.11% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Genmab A (NASDAQ:GMAB)


Genmab A (NASDAQ:GMAB) is the second best biotech stock with a Zen Score of 72, which is 43 points higher than the biotech industry average of 29. It passed 24 out of 33 due diligence checks and has strong fundamentals. Genmab A has seen its stock lose -24.59% over the past year, overperforming other biotech stocks by 19 percentage points.

Genmab A has an average 1 year price target of $37.15, an upside of 16.34% from Genmab A's current stock price of $31.93.

Genmab A stock has a consensus Sell recommendation according to Wall Street analysts. Of the 7 analysts covering Genmab A, 0% have issued a Strong Buy rating, 14.29% have issued a Buy, 57.14% have issued a hold, while 0% have issued a Sell rating, and 28.57% have issued a Strong Sell.

3. Exelixis (NASDAQ:EXEL)


Exelixis (NASDAQ:EXEL) is the third best biotech stock with a Zen Score of 70, which is 41 points higher than the biotech industry average of 29. It passed 22 out of 33 due diligence checks and has strong fundamentals. Exelixis has seen its stock lose -23.22% over the past year, overperforming other biotech stocks by 20 percentage points.

Exelixis has an average 1 year price target of $30.43, an upside of 92.1% from Exelixis's current stock price of $15.84.

Exelixis stock has a consensus Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Exelixis, 28.57% have issued a Strong Buy rating, 57.14% have issued a Buy, 14.29% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 5 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Siga Technologies (NASDAQ:SIGA)


Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 4.41%, which is 3 percentage points higher than the biotech industry average of 1.65%.

Siga Technologies's dividend payout ratio of 46.9% indicates that its dividend yield is sustainable for the long-term.

2. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 1.83%, which is the same as the biotech industry average of 1.65%.

Royalty Pharma's dividend payout ratio of 67.9% indicates that its dividend yield is sustainable for the long-term.

3. Novo Nordisk A S (NYSE:NVO)


Novo Nordisk A S (NYSE:NVO) has an annual dividend yield of 1.61%, which is the same as the biotech industry average of 1.65%. Novo Nordisk A S's dividend payout is not stable, having dropped more than 10% eight times in the last 10 years. Novo Nordisk A S's dividend has not shown consistent growth over the last 10 years.

Novo Nordisk A S's dividend payout ratio of 52.6% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks down?

Biotech stocks were down -1.79% in the last day, and up 0.07% over the last week. Biondvax Pharmaceuticals was the among the top losers in the biotechnology industry, dropping -20.48% yesterday.

BiondVax Pharmaceuticals shares are trading lower after the company filed for an ADS offering.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Vir Biotechnology (NASDAQ:VIR)


Vir Biotechnology (NASDAQ:VIR) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Vir Biotechnology has a valuation score of 100, which is 65 points higher than the biotech industry average of 35. It passed 7 out of 7 valuation due diligence checks.

Vir Biotechnology's stock has dropped -55.72% in the past year. It has underperformed other stocks in the biotech industry by -13 percentage points.

2. Molecular Templates (NASDAQ:MTEM)


Molecular Templates (NASDAQ:MTEM) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Molecular Templates has a valuation score of 100, which is 65 points higher than the biotech industry average of 35. It passed 7 out of 7 valuation due diligence checks.

Molecular Templates's stock has dropped -89.21% in the past year. It has underperformed other stocks in the biotech industry by -46 percentage points.

3. Moderna (NASDAQ:MRNA)


Moderna (NASDAQ:MRNA) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Moderna has a valuation score of 86, which is 51 points higher than the biotech industry average of 35. It passed 6 out of 7 valuation due diligence checks.

Moderna's stock has dropped -68.84% in the past year. It has underperformed other stocks in the biotech industry by -26 percentage points.

Are biotech stocks a good buy now?

48.09% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 101.8% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 14.01x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.